1009735-24-3

Basic information

• Product Name: Methyl 6-broMo-2-Methoxynicotinate
• Synonyms: Methyl 6-broMo-2-Methoxynicotinate
• CAS NO: 1009735-24-3
• Molecular Formula: C8H8BrNO3
• Molecular Weight: 246.05802
• Mol File: 1009735-24-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 296.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.530±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.08±0.10(Predicted)
• CAS DataBase Reference: Methyl 6-broMo-2-Methoxynicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-broMo-2-Methoxynicotinate(1009735-24-3)
• EPA Substance Registry System: Methyl 6-broMo-2-Methoxynicotinate(1009735-24-3)

Safety Data

• Hazardous Substances Data: 1009735-24-3(Hazardous Substances Data)

Usage

General Description

Methyl 6-bromo-2-methoxynicotinate is a chemical compound with the molecular formula C8H8BrNO3. It is a synthetic derivative of niacin, also known as vitamin B3, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drug compounds. The presence of a bromine atom and a methoxy group in the molecular structure makes it a versatile intermediate for the preparation of diverse pharmacologically active molecules. Additionally, it is widely used in organic synthesis and medicinal chemistry as a key starting material for the development of potential therapeutic agents. Overall, Methyl 6-bromo-2-methoxynicotinate plays a crucial role in drug discovery and development due to its unique chemical reactivity and biological properties.

Upstream product

• 1060806-62-3 6-bromo-2-methoxynicotinic acid 
• 74-88-4 methyl iodide 
• 40473-07-2 6-bromo-2-methoxypyridine 

Downstream Products

• 1246765-98-9 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinamide 

Relevant articles and documents

Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5- dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist

A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na+/K+ ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na +/K+ ratio and demonstrated this novel compound acts as an MR antagonist.